Skip to main content
SpringerLink
Log in

Cancer Gene Profiling in Prostate Cancer

  • Protocol
  • First Online:
Cancer Gene Profiling

Part of the book series: Methods in Molecular Biology ((MIMB,volume 576))

Summary

Gene profiling and expression analysis using microarrays have made a significant impact on our biological understanding of prostate cancer. The procedures for generating high-quality expression data from prostate cancer cell lines and tumors are not trivial. However, during the past 9 years, methods by which to process samples for gene profiling have been developed. In this chapter, techniques to process prostate cancer specimens either en bloc (macrodissection) or using laser capture microdissection are presented in detail along with extensive technical notes. Although we focus on prostate cancer and discuss the specific methods utilized in our lab, the processes discussed are generalizable to other tumors and amenable to the substitution of alternative instruments and/or commercially available kits.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    The protocol is derived directly from the Stratagene® Absolutely RNA® Nano Prep Kit Instruction Manual, Catalog #400753, Revision #033001a.

  2. 2.

    The protocol is derived directly from the Ambion® mirVana mi RNA Isolation Kit Instruction Manual, Catalog #1560, Manual Version 0601.

  3. 3.

    The protocol is a modified version of the original provided by Agilent Technologies, Agilent RNA 6000 Pico Kit Guide, Manual PN G2938-90044, Edition 08/2006, Waldbronn Germany, ©Agilent Technologies, Inc. 2006.

  4. 4.

    The protocol is derived from the Golub Lab, Dana-Farber Cancer Institute (14).

  5. 5.

    The protocol is taken from the NuGENâ„¢ Technologies, Inc., Ovationâ„¢ Biotin RNA Amplification and Labeling System Version 1.0 User Guide, Catalog #D01002, Version 09.06.05.

References

  1. Jemal, A., R. Siegel, E. Ward, T. Murray, J. Xu, and M.J. Thun, (2007). Cancer statistics, 2007. CA Cancer J Clin, 57(1), p. 43–66.

    Article  PubMed  Google Scholar 

  2. Tomlins, S.A., D.R. Rhodes, S. Perner, S.M. Dhanasekaran, R. Mehra, X.W. Sun, et al., (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 310(5748), p. 644–8.

    Article  CAS  PubMed  Google Scholar 

  3. Chen, C.D., D.S. Welsbie, C. Tran, S.H. Baek, R. Chen, R. Vessella, et al., (2004). Molecular determinants of resistance to antiandrogen therapy. Nat Med, 10(1), p. 33–9.

    Article  PubMed  Google Scholar 

  4. Stanbrough, M., G.J. Bubley, K. Ross, T.R. Golub, M.A. Rubin, T.M. Penning, et al., (2006). Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res, 66(5), p. 2815–25.

    Article  CAS  PubMed  Google Scholar 

  5. Holzbeierlein, J., P. Lal, E. LaTulippe, A. Smith, J. Satagopan, L. Zhang, et al., (2004).Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol, 164(1), p. 217–27.

    CAS  PubMed  Google Scholar 

  6. Tomlins, S.A., R. Mehra, D.R. Rhodes, X. Cao, L. Wang, S.M. Dhanasekaran, et al., (2007).Integrative molecular concept modeling of prostate cancer progression. Nat Genet, 39(1), p. 41–51.

    Article  CAS  PubMed  Google Scholar 

  7. Dhanasekaran, S.M., T.R. Barrette, D. Ghosh, R. Shah, S. Varambally, K. Kurachi, et al., (2001). Delineation of prognostic biomarkers in prostate cancer. Nature, 412(6849), p. 822–6.

    Article  CAS  PubMed  Google Scholar 

  8. Lapointe, J., C. Li, J.P. Higgins, M. van de Rijn, E. Bair, K. Montgomery, et al., (2004).Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA, 101(3), p. 811–6.

    Article  CAS  PubMed  Google Scholar 

  9. Luo, J., S. Zha, W.R. Gage, T.A. Dunn, J.L. Hicks, C.J. Bennett, et al., (2002). Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res, 62(8), p. 2220–6.

    CAS  PubMed  Google Scholar 

  10. Luo, J., D.J. Duggan, Y. Chen, J. Sauvageot, C.M. Ewing, M.L. Bittner, et al., (2001).Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res, 61(12), p. 4683–8.

    CAS  PubMed  Google Scholar 

  11. Singh, D., P.G. Febbo, K. Ross, D.G. Jackson, J. Manola, C. Ladd, et al., (2002).Gene expression correlates of clinical prostate cancer behavior. Cancer Cell, 1(2), p. 203–9.

    Article  CAS  PubMed  Google Scholar 

  12. Welsh, J.B., L.M. Sapinoso, A.I. Su, S.G. Kern, J. Wang-Rodriguez, C.A. Moskaluk, et al., (2001). Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res, 61(16), p. 5974–8.

    CAS  PubMed  Google Scholar 

  13. Rubin, M.A., M. Zhou, S.M. Dhanasekaran, S. Varambally, T.R. Barrette, M.G. Sanda, et al., (2002). Alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA, 287(13), p. 1662–70.

    Article  CAS  PubMed  Google Scholar 

  14. Febbo, P.G., A. Thorner, M.A. Rubin, M. Loda, P.W. Kantoff, W.K. Oh, et al., (2006).Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res, 12(1), p. 152–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine and Molecular Genetics and Microbiology, Duke Institute for Genome Science and Policy, Duke University, Durham, NC, USA

    Adam Foye & Phillip G. Febbo

Authors
  1. Adam Foye
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Phillip G. Febbo
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medizinische Fak. Carl Gustav Carus, TU Dresden, Fetscherstr. 74, Dresden, 01307, Germany

    Robert Grützmann

  2. Klinik und Poliklinik für, TU Dresden, Fetscherstraße 74, Dresden, 01307, Germany

    Christian Pilarsky

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Foye, A., Febbo, P.G. (2009). Cancer Gene Profiling in Prostate Cancer. In: Grützmann, R., Pilarsky, C. (eds) Cancer Gene Profiling. Methods in Molecular Biology, vol 576. Humana Press. https://doi.org/10.1007/978-1-59745-545-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-545-9_15

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-76-3

  • Online ISBN: 978-1-59745-545-9

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation